ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0096

Three-Month Clinical, Functional, and Mental Outcomes in Kidney Transplant Recipients Surviving COVID-19

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Duivenvoorden, Raphael, Radboudumc, Nijmegen, Gelderland, Netherlands
  • Vart, Priya, Universitair Medisch Centrum Groningen, Groningen, Groningen, Netherlands
  • Noordzij, Marlies, Universitair Medisch Centrum Groningen, Groningen, Groningen, Netherlands
  • Soares dos Santos Jr, Augusto Cesar, Hospital das Clinicas at Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
  • Zulkarnaev, Alex B., Moskovskij oblastnoj naucno-issledovatel'skij kliniceskij institut imeni M F Vladimirskogo, Moskva, Moskva, Russian Federation
  • Franssen, Casper F.M., Universitair Medisch Centrum Groningen, Groningen, Groningen, Netherlands
  • Kuypers, Dirk R., Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Flanders, Belgium
  • Demir, Erol, Istanbul Universitesi Istanbul Tip Fakultesi, Istanbul, Istanbul, Turkey
  • Rahimzadeh, Hormat, Sina Hospital, Tehran, Tehran, Iran (the Islamic Republic of)
  • Kerschbaum, Julia, Medizinische Universitat Innsbruck Universitatsklinik fur Innere Medizin IV Nephrologie und Hypertensiologie, Innsbruck, Austria
  • Jager, Kitty J., Amsterdam Universitair Medische Centra, Duivendrecht, Noord-Holland, Netherlands
  • Turkmen, Kultigin, Necmettin Erbakan Universitesi Meram Tip Fakultesi, Meram, Konya, Turkey
  • Hemmelder, Marc H., Universiteit Maastricht, Maastricht, Limburg, Netherlands
  • Schouten, Marcel, Tergooi, Hilversum, North Holland, Netherlands
  • Rodríguez-Ferrero, María L., Hospital General Universitario Gregorio Maranon, Madrid, Madrid, Spain
  • Crespo, Marta, Hospital del Mar, Barcelona, Catalunya, Spain
  • Gansevoort, Ron T., Universitair Medisch Centrum Groningen, Groningen, Groningen, Netherlands
  • Hilbrands, Luuk, Radboudumc, Nijmegen, Gelderland, Netherlands
Background

Kidney transplant patients are at high risk for COVID-19 related mortality. However, limited data are available on longer term clinical, functional and mental outcomes in patients that survive COVID-19.

Methods

Data from adult kidney transplant patients that presented with COVID-19 between February 1st, 2020 and January 31st, 2021 were retrieved from the ERACODA database. Data from patients with complete data for vital status, hospitalization and/or ICU admission was used for this analysis.

Results

912 patients were included with a mean age of 56.7 (±13.7) years. 26.4% were not hospitalized, 57.5% hospitalized, and 16.1% hospitalized and ICU admitted. Three-months survival was 82.3% overall and 98.8%, 84.2% and 49.0% resp. in each group. Three-months acute rejection, need for dialysis / CVVH at any time point, and graft failure occurred in the overall group in 1.0%, 2.6% and 1.8% resp., and in 2.1%, 10.6% and 10.6% of ICU admitted patients resp. Of the surviving patients 83.3% had reached their prior functional status within 3 months. Of patients that had not yet reached their prior functional status, it was expected that 79.6% still would do so within the coming year. 94.4% had reached their prior mental status. Of patients that had not yet reached their prior mental status, it was expected that 80% of patients would do so within the coming year.

Conclusion

In patients alive at three-months follow-up, graft loss was rare, and most patients had reached their pre-COVID-19 functional and mental status.

Table 1
OutcomesTotalNot hospitalizedHospitalized, no ICUHospitalized, ICUp-value
Acute rejection, n (%)5 (1.0)2 (1.4)2 (0.7)1 (2.1)0.57
Required dialysis / CVVH, n (%)13 (2.6)3 (2.1)5 (1.7)5 (10.6)<0.001
Graft Loss, n (%)9 (1.8)1 (0.7)3 (1.0)5 (10.6)<0.001
Reached pre-COVID-19 functional status, n (%)375 (83.3)123 (87.9)235 (87.0)17 (42.5)<0.001
Reached pre-COVID-19 mental status, n (%)425 (94.4)134 (95.7)260 (96.3)31 (77.5)<0.001

Clinical, functional, and mental outcomes in kidney transplant recipients three months after being diagnosed with COVID-19. Data of 487 patients were available for analysis of graft function related outcomes. Data of 450 patients were available for functional and mental status outcomes.